WO2012140424A3 - Composition - Google Patents

Composition Download PDF

Info

Publication number
WO2012140424A3
WO2012140424A3 PCT/GB2012/050802 GB2012050802W WO2012140424A3 WO 2012140424 A3 WO2012140424 A3 WO 2012140424A3 GB 2012050802 W GB2012050802 W GB 2012050802W WO 2012140424 A3 WO2012140424 A3 WO 2012140424A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
toxin
fused
vaccine compositions
conjugated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2012/050802
Other languages
English (en)
Other versions
WO2012140424A2 (fr
Inventor
Guillaume Stewart-Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of WO2012140424A2 publication Critical patent/WO2012140424A2/fr
Publication of WO2012140424A3 publication Critical patent/WO2012140424A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une composition immunogène comprenant i) un premier antigène ; et ii) un second antigène lié à une toxine, la composition étant apte à susciter une réponse immunitaire au premier antigène lorsqu'elle est administrée à un être humain ou à un animal non humain. L'invention concerne également des utilisations de la composition immunogène et une composition pharmaceutique ou un coffret comprenant la composition immunogène.
PCT/GB2012/050802 2011-04-14 2012-04-12 Composition Ceased WO2012140424A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1106340.1A GB201106340D0 (en) 2011-04-14 2011-04-14 Composition
GB1106340.1 2011-04-14

Publications (2)

Publication Number Publication Date
WO2012140424A2 WO2012140424A2 (fr) 2012-10-18
WO2012140424A3 true WO2012140424A3 (fr) 2013-01-24

Family

ID=44147021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/050802 Ceased WO2012140424A2 (fr) 2011-04-14 2012-04-12 Composition

Country Status (2)

Country Link
GB (1) GB201106340D0 (fr)
WO (1) WO2012140424A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040242A1 (fr) * 1995-06-07 1996-12-19 Smithkline Beecham Biologicals S.A. Vaccins comprenant un conjugue antigene de polysaccharide-proteine porteuse et une proteine porteuse libre
US20030194411A1 (en) * 1991-04-02 2003-10-16 Arye Rubinstein Peptide compositions for the treatment and prevention of HIV infection
WO2007062831A1 (fr) * 2005-11-30 2007-06-07 Glaxosmithkline Biologicals S.A. Vaccins
US20100196451A1 (en) * 2005-11-30 2010-08-05 Glaxosmithkline Biologicals Vaccines Containing Non-Live Antigenic Vectors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194411A1 (en) * 1991-04-02 2003-10-16 Arye Rubinstein Peptide compositions for the treatment and prevention of HIV infection
WO1996040242A1 (fr) * 1995-06-07 1996-12-19 Smithkline Beecham Biologicals S.A. Vaccins comprenant un conjugue antigene de polysaccharide-proteine porteuse et une proteine porteuse libre
WO2007062831A1 (fr) * 2005-11-30 2007-06-07 Glaxosmithkline Biologicals S.A. Vaccins
US20100196451A1 (en) * 2005-11-30 2010-08-05 Glaxosmithkline Biologicals Vaccines Containing Non-Live Antigenic Vectors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NACHREINER T ET AL: "Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 195, no. 1-2, 1 March 2008 (2008-03-01), pages 28 - 35, XP022612044, ISSN: 0165-5728, [retrieved on 20080215], DOI: 10.1016/J.JNEUROIM.2008.01.001 *
STOCKER ET AL: "Antigen-specific targeting and elimination of EBV-transformed B cells by allergen toxins", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US, vol. 116, no. 4, 1 October 2005 (2005-10-01), pages 910 - 915, XP005094487, ISSN: 0091-6749, DOI: 10.1016/J.JACI.2005.07.022 *

Also Published As

Publication number Publication date
WO2012140424A2 (fr) 2012-10-18
GB201106340D0 (en) 2011-06-01

Similar Documents

Publication Publication Date Title
EP4056198A3 (fr) Vésicules de membrane externe
WO2008021076A3 (fr) Vaccins à base de matrice protéique et procédés de fabrication et d'administration de tels vaccins
CO6781540A2 (es) Protéinas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae
CL2012002195A1 (es) Composicion inmunogénica que comprende una mezcla de conjugados de polisacaridos-proteina multivalente que consiste en polisacáridos capsulares de streptococcus pneumoniae; metodo para inducir una respuesta inmune a un polisacarido capsular de streptococcus pneumoniae.
WO2012006369A3 (fr) Immunisation de grands mammifères à l'aide de faibles doses d'arn
WO2013177214A3 (fr) Focalisation d'épitope par concentration de surface effective variable d'antigène
MY169837A (en) Immunogenic compositions of staphylococcus aureus antigens
PH12014501835A1 (en) Novel adjuvant compositions
CO7240387A2 (es) Composición conjugada de polisacáridos-proteínas neumocócica polivalente
WO2014107652A3 (fr) Vaccins à forte densité en antigènes carbohydrates et comportant un adjuvant inédit à base de saponine
NZ708065A (en) Novel mucosal adjuvants and delivery systems
NZ628449A (en) Neisseria meningitidis compositions and methods thereof
CR10559A (es) Vacuna de influenza
WO2008148057A3 (fr) Compositions et procédés pour améliorer la réponse immunitaire à des vaccins
WO2014207708A3 (fr) Conjugués acide aminé et peptide et procédé de conjugaison
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
WO2010103017A3 (fr) Conjugués haptène-support liés à des toxines bactériennes et ayant un peptide signal comme support, et leur utilisation dans des compositions immunogènes
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MX2015017257A (es) Composiciones y metodos de inmunizar contra clostridium difficile.
DK3016673T3 (da) Pattedyrsmælkeosteopontin til forbedring af immunreaktion
WO2012118559A3 (fr) Vaccin contre la dengue tétravalent et mixte bivalent
WO2011100508A3 (fr) Procédés et compositions liés à des fusions glycoprotéine-immunoglobuline
WO2012058957A3 (fr) Extraits de polysaccharides d'épimède, fractions de ces extraits et utilisations dans des adjuvants de vaccins
WO2012103444A3 (fr) Compositions et réactifs immunogènes pour une préparation
WO2011084967A3 (fr) Procédés et compositions visant à conférer une immunité protectrice aux personnes âgées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12719789

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12719789

Country of ref document: EP

Kind code of ref document: A2